- Home
- HI vs TARS Comparison
HI vs TARS Comparison
Compare HI & TARS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HI
- TARS
- Stock Information
- Founded
- HI 2007
- TARS 2016
- Country
- HI United States
- TARS United States
- Employees
- HI N/A
- TARS N/A
- Industry
- HI Miscellaneous manufacturing industries
- TARS Medicinal Chemicals and Botanical Products
- Sector
- HI Consumer Discretionary
- TARS Health Care
- Exchange
- HI Nasdaq
- TARS Nasdaq
- Market Cap
- HI 2.2B
- TARS 1.8B
- IPO Year
- HI N/A
- TARS 2020
- Fundamental
- Price
- HI $32.78
- TARS $44.83
- Analyst Decision
- HI Buy
- TARS Strong Buy
- Analyst Count
- HI 3
- TARS 5
- Target Price
- HI $44.67
- TARS $54.20
- AVG Volume (30 Days)
- HI 401.6K
- TARS 1.1M
- Earning Date
- HI 11-13-2024
- TARS 11-13-2024
- Dividend Yield
- HI 2.72%
- TARS N/A
- EPS Growth
- HI N/A
- TARS N/A
- EPS
- HI N/A
- TARS N/A
- Revenue
- HI $3,182,800,000.00
- TARS $129,621,000.00
- Revenue This Year
- HI $14.37
- TARS $852.60
- Revenue Next Year
- HI N/A
- TARS $74.21
- P/E Ratio
- HI N/A
- TARS N/A
- Revenue Growth
- HI 12.63
- TARS 801.96
- 52 Week Low
- HI $25.11
- TARS $15.60
- 52 Week High
- HI $50.58
- TARS $52.99
- Technical
- Relative Strength Index (RSI)
- HI 63.85
- TARS 57.98
- Support Level
- HI $30.04
- TARS $46.22
- Resistance Level
- HI $35.33
- TARS $52.99
- Average True Range (ATR)
- HI 1.09
- TARS 3.62
- MACD
- HI 0.44
- TARS -0.33
- Stochastic Oscillator
- HI 68.00
- TARS 42.09
About HI Hillenbrand Inc
Hillenbrand Inc is a U.S.-based company that operates through three segments. The Advanced Process Solutions segment designs, develops, manufactures, and services engineered industrial equipment. The Molding Technology Solutions segment offers engineered and customized systems in plastic technology and processing. Batesville designs provides, and markets funeral services and solutions.
About TARS Tarsus Pharmaceuticals Inc.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. It is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis.